Home News Healthcare

Boehringer Ingelheim to acquire assets, IP from Singapore biotech firm in deal worth more than US$1 bil

Stanislaus Jude Chan
Stanislaus Jude Chan1/9/2020 03:21 PM GMT+08  • 2 min read
Boehringer Ingelheim to acquire assets, IP from Singapore biotech firm in deal worth more than US$1 bil
The deal is the largest for any biotech company in Singapore, and among the biggest globally for preclinical stage programmes.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (Jan 9): German pharmaceutical giant Boehringer Ingelheim is acquiring assets and intellectual property from Singapore-based biotech company Enleofen Bio, in a step towards finding effective treatments for fibro-inflammatory diseases.

In a press release on Thursday, Enleofen says Boehringer Ingelheim has acquired worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform.

For each new product, Boehringer Ingelheim will pay Enleofen earnout payments of more than US$1 billion ($1.35 billion) in upfront and success-based development and commercialisation milestones.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now